Sangamo (SGMO) announced updated data from the Phase 1/2 STAAR study evaluating isaralgagene civaparvovec, or ST-920, a wholly owned gene therapy product candidate for the treatment of Fabry ...

In a report released today, Ritu Baral from TD Cowen maintained a Buy rating on Sangamo Biosciences (SGMO – Research Report). The company’s shares closed yesterday at $1.27. Leverage the power ...

It was an important day for conference battles as the regular season nears it's conclusionSangamo Standings (Top 4):1.

Pfizer terminated partnership with Sangamo on hemophilia A gene therapy despite positive Phase 3 data. Find out why SGMO ...

It was a day full of basketball at Williamsville as two conferences went head to head throughout the day, the Illini Prairie ...

Register's athlete of the week nominees. The poll closes at noon on Friday. Information about the nominees is below. Kincaid ...

Sangamo Therapeutics (NASDAQ:SGMO) reported positive updated data from a Phase 1/2 study of its gene therapy candidate isaralgagene civaparvovec, or ST-920, in the treatment of Fabry disease. The ...

RICHMOND, Calif. - Sangamo Therapeutics, Inc. (NASDAQ: SGMO), a genomic medicine company with a market capitalization of $263 million, has announced promising updated results from its Phase 1/2 ...

Springfield City Council will consider bills Monday night to approve a budget for the Springfield Art Museum’s renovation ...

Now Gilead is spending a further $150 million upfront to access the cutting edge gene-editing technology of another Californian biotech, Sangamo. The ambition for this cancer-focused collaboration ...

in a Sangamo Conference matchup with Pleasant Plains. “It really sucked not being able to play, but I think I worked hard to get better and I feel great.” Need a break? Play the USA TODAY ...